AIMS: Impaired liver function often necessitates drug dose adjustment to avoid excessive drug accumulation and adverse events, but a marker for the extent of the required adjustment is lacking. The aim of this study was to investigate whether Child-Pugh (CP) and model for end-stage liver disease (MELD) scores correlate with drug clearance. METHODS: Midazolam was used as a CYP3A probe and its pharmacokinetics were analyzed in 24 patients with mild to severe liver cirrhosis (n = 4, 10 and 10 with CP class A, B and C, respectively) and six patients without liver disease. RESULTS: Both scores correlated well with unbound midazolam clearance (CLu ), unbound midazolam fraction and half-life (all P < 0.01), whereas the unbound steady-state volume of distribution was not significantly changed. In patients with severe liver cirrhosis unbound midazolam clearance was only 14% of controls (CP C: CLu = 843 ± 346 l h(-1), MELD ≥ 15: CLu = 805 ± 474 l h(-1), controls: CLu = 5815 ± 2649 l h(-1), P < 0.01). CONCLUSION: The correlation with unbound midazolam clearance suggests that either score predicts the metabolic capacity of CYP3A, the most relevant drug metabolizing enzyme subfamily in humans.
AIMS: Impaired liver function often necessitates drug dose adjustment to avoid excessive drug accumulation and adverse events, but a marker for the extent of the required adjustment is lacking. The aim of this study was to investigate whether Child-Pugh (CP) and model for end-stage liver disease (MELD) scores correlate with drug clearance. METHODS:Midazolam was used as a CYP3A probe and its pharmacokinetics were analyzed in 24 patients with mild to severe liver cirrhosis (n = 4, 10 and 10 with CP class A, B and C, respectively) and six patients without liver disease. RESULTS: Both scores correlated well with unbound midazolam clearance (CLu ), unbound midazolam fraction and half-life (all P < 0.01), whereas the unbound steady-state volume of distribution was not significantly changed. In patients with severe liver cirrhosis unbound midazolam clearance was only 14% of controls (CP C: CLu = 843 ± 346 l h(-1), MELD ≥ 15: CLu = 805 ± 474 l h(-1), controls: CLu = 5815 ± 2649 l h(-1), P < 0.01). CONCLUSION: The correlation with unbound midazolam clearance suggests that either score predicts the metabolic capacity of CYP3A, the most relevant drug metabolizing enzyme subfamily in humans.
Authors: R H Wiesner; S V McDiarmid; P S Kamath; E B Edwards; M Malinchoc; W K Kremers; R A Krom; W R Kim Journal: Liver Transpl Date: 2001-07 Impact factor: 5.799
Authors: L Veronese; J Rautaureau; B M Sadler; C Gillotin; J P Petite; B Pillegand; M Delvaux; C Masliah; S Fosse; Y Lou; D S Stein Journal: Antimicrob Agents Chemother Date: 2000-04 Impact factor: 5.191
Authors: Gordon Jung-Hyuk Park; Peter Harry Katelaris; D Brian Jones; Francis Seow; David George Le Couteur; Meng Chong Ngu Journal: Hepatology Date: 2003-11 Impact factor: 17.425
Authors: Hong Chen; Zhong-Yang Shen; Wang Xu; Tie-Yan Fan; Jun Li; Yuan-Fu Lu; Ming-Liang Cheng; Jie Liu Journal: World J Gastroenterol Date: 2014-07-14 Impact factor: 5.742
Authors: Matthew P Kosloski; Haoyu Wang; David Pugatch; Federico J Mensa; Edward Gane; Eric Lawitz; Thomas C Marbury; Richard A Preston; Jens Kort; Wei Liu Journal: Eur J Clin Pharmacol Date: 2018-10-19 Impact factor: 2.953